vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and N-able, Inc. (NABL). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $130.3M, roughly 1.3× N-able, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 11.8%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 7.0%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Able UK is a British industrial services company specialising in decommissioning of ships and offshore installations.
ESPR vs NABL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $130.3M |
| Net Profit | — | — |
| Gross Margin | — | 76.2% |
| Operating Margin | 50.6% | 10.2% |
| Net Margin | — | — |
| Revenue YoY | 143.7% | 11.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $130.3M | ||
| Q3 25 | $87.3M | $131.7M | ||
| Q2 25 | $82.4M | $131.2M | ||
| Q1 25 | $65.0M | $118.2M | ||
| Q4 24 | $69.1M | $116.5M | ||
| Q3 24 | $51.6M | $116.4M | ||
| Q2 24 | $73.8M | $119.4M | ||
| Q1 24 | $137.7M | $113.7M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $1.4M | ||
| Q2 25 | $-12.7M | $-4.0M | ||
| Q1 25 | $-40.5M | $-7.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $10.8M | ||
| Q2 24 | $-61.9M | $9.5M | ||
| Q1 24 | $61.0M | $7.5M |
| Q4 25 | — | 76.2% | ||
| Q3 25 | — | 77.5% | ||
| Q2 25 | — | 78.1% | ||
| Q1 25 | — | 76.6% | ||
| Q4 24 | — | 80.0% | ||
| Q3 24 | — | 82.9% | ||
| Q2 24 | — | 84.0% | ||
| Q1 24 | — | 83.9% |
| Q4 25 | 50.6% | 10.2% | ||
| Q3 25 | -11.4% | 8.8% | ||
| Q2 25 | 8.6% | 7.7% | ||
| Q1 25 | -34.0% | 1.5% | ||
| Q4 24 | -6.4% | 13.7% | ||
| Q3 24 | -31.0% | 20.5% | ||
| Q2 24 | 3.5% | 18.4% | ||
| Q1 24 | 52.5% | 18.0% |
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 1.1% | ||
| Q2 25 | -15.4% | -3.1% | ||
| Q1 25 | -62.2% | -6.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | 9.2% | ||
| Q2 24 | -83.9% | 7.9% | ||
| Q1 24 | 44.3% | 6.6% |
| Q4 25 | $0.32 | $-0.04 | ||
| Q3 25 | $-0.16 | $0.01 | ||
| Q2 25 | $-0.06 | $-0.02 | ||
| Q1 25 | $-0.21 | $-0.04 | ||
| Q4 24 | $-0.14 | $0.01 | ||
| Q3 24 | $-0.15 | $0.06 | ||
| Q2 24 | $-0.33 | $0.05 | ||
| Q1 24 | $0.34 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $111.8M |
| Total DebtLower is stronger | — | $393.9M |
| Stockholders' EquityBook value | $-302.0M | $804.7M |
| Total Assets | $465.9M | $1.4B |
| Debt / EquityLower = less leverage | — | 0.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $111.8M | ||
| Q3 25 | $92.4M | $101.4M | ||
| Q2 25 | $86.1M | $93.9M | ||
| Q1 25 | $114.6M | $94.1M | ||
| Q4 24 | $144.8M | $85.2M | ||
| Q3 24 | $144.7M | $174.4M | ||
| Q2 24 | $189.3M | $157.5M | ||
| Q1 24 | $226.6M | $139.2M |
| Q4 25 | — | $393.9M | ||
| Q3 25 | — | $331.7M | ||
| Q2 25 | — | $332.1M | ||
| Q1 25 | — | $332.6M | ||
| Q4 24 | — | $333.1M | ||
| Q3 24 | — | $333.6M | ||
| Q2 24 | — | $334.1M | ||
| Q1 24 | — | $334.5M |
| Q4 25 | $-302.0M | $804.7M | ||
| Q3 25 | $-451.4M | $813.4M | ||
| Q2 25 | $-433.5M | $809.4M | ||
| Q1 25 | $-426.2M | $775.1M | ||
| Q4 24 | $-388.7M | $759.3M | ||
| Q3 24 | $-370.2M | $765.0M | ||
| Q2 24 | $-344.2M | $724.4M | ||
| Q1 24 | $-294.3M | $709.1M |
| Q4 25 | $465.9M | $1.4B | ||
| Q3 25 | $364.0M | $1.4B | ||
| Q2 25 | $347.1M | $1.4B | ||
| Q1 25 | $324.0M | $1.4B | ||
| Q4 24 | $343.8M | $1.3B | ||
| Q3 24 | $314.1M | $1.2B | ||
| Q2 24 | $352.3M | $1.2B | ||
| Q1 24 | $373.1M | $1.1B |
| Q4 25 | — | 0.49× | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.44× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.46× | ||
| Q1 24 | — | 0.47× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $25.3M |
| Free Cash FlowOCF − Capex | — | $20.9M |
| FCF MarginFCF / Revenue | — | 16.0% |
| Capex IntensityCapex / Revenue | 0.0% | 3.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $75.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $25.3M | ||
| Q3 25 | $-4.3M | $24.0M | ||
| Q2 25 | $-31.4M | $24.2M | ||
| Q1 25 | $-22.6M | $19.7M | ||
| Q4 24 | $-35.0M | $26.0M | ||
| Q3 24 | $-35.3M | $22.0M | ||
| Q2 24 | $-7.2M | $27.3M | ||
| Q1 24 | $53.8M | $4.2M |
| Q4 25 | — | $20.9M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | — | $20.4M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $18.8M | ||
| Q3 24 | $-35.5M | $18.2M | ||
| Q2 24 | $-7.3M | $24.0M | ||
| Q1 24 | $53.8M | $746.0K |
| Q4 25 | — | 16.0% | ||
| Q3 25 | — | 13.2% | ||
| Q2 25 | — | 15.5% | ||
| Q1 25 | — | 13.9% | ||
| Q4 24 | — | 16.2% | ||
| Q3 24 | -68.7% | 15.7% | ||
| Q2 24 | -9.9% | 20.1% | ||
| Q1 24 | 39.0% | 0.7% |
| Q4 25 | 0.0% | 3.4% | ||
| Q3 25 | 0.0% | 5.0% | ||
| Q2 25 | 0.0% | 2.9% | ||
| Q1 25 | 0.0% | 2.8% | ||
| Q4 24 | 0.0% | 6.1% | ||
| Q3 24 | 0.3% | 3.2% | ||
| Q2 24 | 0.1% | 2.7% | ||
| Q1 24 | 0.1% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 17.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.04× | ||
| Q2 24 | — | 2.89× | ||
| Q1 24 | 0.88× | 0.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
NABL
| Transferred Over Time | $121.9M | 94% |
| Transferred At Point In Time | $8.4M | 6% |
| Other Revenue | $1.3M | 1% |
